Quick Heal Technologies Ltd

- Quick Heal Technologies currently holds a strong balance sheet with INR 191 crores cash and investments as of September 30, 2025. - Management has not disclosed any immediate plans for new fundraising through debt or equity. - They continuously evaluate options for investments, including potential M&A or acquisitions, and will update investors as appropriate. - Any deployment of cash reserves for growth or acquisitions will be aligned with company strategy and board approval. - There is no specific mention of raising fresh funds through debt or equity in the current quarter or near future from the provided transcript.

- The company maintains a strong balance sheet with INR 191 crores cash balance as of 30th September 2025, offering flexibility for investments. - They are actively evaluating options for M&A and strategic acquisitions aligned with their vision and roadmap. - Investments in R&D remain a priority, with ongoing optimization through AI and automation to sustain product innovation. - There are no specific disclosed plans for large current capex, but the firm continues expanding sales and marketing teams, especially for Enterprise growth. - The company is focused on leveraging government and international market opportunities, especially through Make in India initiatives, but concrete capex figures or timelines were not detailed. - Overall, capital allocation is strategically measured to balance growth in Enterprise and Consumer businesses and continuous R&D investments.

- Enterprise business is expected to become the dominant revenue contributor soon, overtaking Consumer business, which is structurally declining. - Total Addressable Market (TAM) is projected to increase from INR 1,800 crores to INR 4,000 crores. - Enterprise segment expected to contribute around 80% of the INR 4,000 crores TAM; Consumer around 20%. - International revenue currently constitutes about 20% of Enterprise revenue. - Government segment and international markets targeted for significant growth. - New products such as data privacy solutions, threat intelligence platforms, EDR, XDR, STI, and SMAP expected to drive growth. - Focus on mid-market and SMB enterprises with 1,000-5,000 endpoints. - Continued investments in R&D and sales/marketing to support revenue growth. - Consumer business revenue will largely remain stable, aiming to hold market share amid decline. - Revenue for Q2 FY ’26 was INR 83.5 crores, showing healthy growth compared to prior periods.

- Quick Heal Technologies expects steady growth driven by both Consumer and Enterprise segments, with Enterprise set to take a larger revenue share soon (currently around 60-40 split). - Enterprise segment, especially mid-market and government sectors, is a key growth lever with increasing traction in products like EDR, XDR, STI, and SMAP. - Revenue for Q2 FY26 grew 14% YoY to INR 83.5 crores with an EBITDA margin of around 11%. - R&D investments are ongoing but optimized using AI and automation; these expenses are expensed fully and impact EBITDA. - Management is cautious on giving specific revenue/EPS guidance but expects that increased enterprise revenue and operational efficiencies will improve margins and profitability. - Marketing and sales investments, especially for Enterprise, will continue proportional to revenue growth. - Government sector and international markets (20% of revenues) represent significant growth opportunities. - Overall, longer-term profitability is expected to improve as Enterprise segment scales and R&D investments yield product benefits.

The transcript does not specifically disclose current or expected orderbook or pending orders figures. However, some related points include: - The company has a "heavily business pipeline" and a growing international presence, indicating a healthy flow of prospective deals. - Government business is showing robust growth with some delays due to big-ticket decision timelines. - Enterprise business continues steady growth with strong partners and traction across key segments. - New products like data privacy solutions and threat intelligence platforms are gaining initial interest. - The company is actively pursuing government and international opportunities under Make in India initiatives. - Enterprise segment, especially mid-market and government, is expected to be a key lever for growth over the next 2-3 years. No explicit orderbook or pending order values are mentioned.